Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Archive ouverte

Camus, Vincent | Rossi, Cédric | Sesques, Pierre | Lequesne, Justine | Tonnelet, David | Haioun, Corinne | Durot, Eric | Willaume, Alexandre | Gauthier, Martin | Moles-Moreau, Marie-Pierre | Antier, Chloé | Lazarovici, Julien | Monjanel, Hélène | Bernard, Sophie | Tardy, Magalie | Besson, Caroline | Lebras, Laure | Choquet, Sylvain | Le Du, Katell | Bonnet, Christophe | Bailly, Sarah | Damaj, Ghandi | Laribi, Kamel | Maisonneuve, Hervé | Houot, Roch | Chauchet, Adrien | Jardin, Fabrice | Traverse-Glehen, Alexandra | Decazes, Pierre | Becker, Stéphanie | Berriolo-Riedinger, Alina | Tilly, Hervé

Edité par CCSD ; The American Society of Hematology -

International audience. Abstract Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion